Name: Name:4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(oxan-4-ylmethyl)amino]benzene}sulfonyl)-2-{1H-pyrrolo[2,3-b]pyridin-5-yloxy}benzamide
Brand: AABLOCKS
SKU: AA000OG2
Rating: 90 (10 reviews)

Catalog No.: AA000OG2

1257044-40-8 | 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(oxan-4-ylmethyl)amino]benzene}sulfonyl)-2-{1H-pyrrolo[2,3-b]pyridin-5-yloxy}benzamide

Pack Size： 2mg

Purity： 99%

in stock

$9.00 $6.00

Pack Size： 25mg

Purity： 99%

in stock

$49.00 $34.00

Pack Size： 100mg

Purity： 99%

in stock

$52.00 $36.00

Pack Size： 250mg

Purity： 99%

in stock

$106.00 $74.00

Pack Size： 1g

Purity： 99%

in stock

$109.00 $76.00

Pack Size： 5g

Purity： 97%

in stock

$520.00 $364.00

Pack Size： 10g

Purity： 97%

in stock

$964.00 $675.00

Pack Size： 25g

Purity： 97%

in stock

$1,918.00 $1,343.00

Pack Size： 100g

Purity： 97%

in stock

$5,731.00 $4,012.00

Quantity

- +

Add to Card

Order Now

bulk Quotation Request

Technical Information

Catalog Number: AA000OG2

Chemical Name: 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(oxan-4-ylmethyl)amino]benzene}sulfonyl)-2-{1H-pyrrolo[2,3-b]pyridin-5-yloxy}benzamide

CAS Number: 1257044-40-8

Molecular Formula: C45H50ClN7O7S

Molecular Weight: 868.4392

MDL Number: MFCD23160052

SMILES: Clc1ccc(cc1)C1=C(CCC(C1)(C)C)CN1CCN(CC1)c1ccc(c(c1)Oc1cnc2c(c1)cc[nH]2)C(=O)NS(=O)(=O)c1ccc(c(c1)[N+](=O)[O-])NCC1CCOCC1

Properties

Form: Solid

MP: 129-163ºC

Storage: Light sensitive;Keep in dry area;-20 ℃;

Complexity: 1640

Covalently-Bonded Unit Count: 1

Defined Atom Stereocenter Count: 0

Defined Bond Stereocenter Count: 0

Formal Charge: 0

Heavy Atom Count: 61

Hydrogen Bond Acceptor Count: 11

Hydrogen Bond Donor Count: 3

Isotope Atom Count: 0

Rotatable Bond Count: 12

Undefined Atom Stereocenter Count: 0

Undefined Bond Stereocenter Count: 0

XLogP3: 8.2

Downstream Synthesis Route

1228779-96-1

1235865-77-6

1257044-40-8

[1]Patent:CN108997333,2018,A.Locationinpatent:Paragraph0065;0067;0075;0084;0094;0103;0113

[2]JournalofOrganicChemistry,2019,vol.84,p.4814-4829

[3]Patent:US2014/275540,2014,A1.Locationinpatent:Paragraph0163;0164

[4]Patent:CN104370905,2016,B.Locationinpatent:Paragraph0030;0031;0036;0037

[5]Patent:WO2017/156398,2017,A1.Locationinpatent:Paragraph0253;0254;0255;0256;0257;0258;0259-0261

[6]Patent:WO2012/71336,2012,A1.Locationinpatent:Page/Pagecolumn20

[7]Patent:WO2018/29711,2018,A2.Locationinpatent:Page/Pagecolumn37;38;39

[8]Patent:US2010/305122,2010,A1.Locationinpatent:Page/Pagecolumn122

[9]Patent:WO2016/24230,2016,A1.Locationinpatent:Paragraph00749

[10]Patent:US10213433,2019,B2.Locationinpatent:Page/Pagecolumn17

[11]Patent:WO2011/150016,2011,A1.Locationinpatent:Page/Pagecolumn82

[12]Patent:WO2017/212431,2017,A1.Locationinpatent:Page/Pagecolumn66

[13]Patent:WO2018/225043,2018,A1.Locationinpatent:Page/Pagecolumn17;18

130290-79-8

406233-31-6

1257044-40-8

[1]Patent:WO2011/150016,2011,A1

[2]Patent:WO2016/24230,2016,A1

183208-35-7

1257044-40-8

[1]Patent:WO2011/150016,2011,A1

[2]Patent:WO2012/71336,2012,A1

[3]Patent:WO2016/24230,2016,A1

[4]Patent:WO2018/29711,2018,A2

[5]Patent:US10213433,2019,B2

858116-66-2

1257044-40-8

[1]Patent:WO2011/150016,2011,A1

[2]Patent:WO2012/71336,2012,A1

[3]Patent:WO2016/24230,2016,A1

[4]Patent:US10213433,2019,B2

32767-46-7

1257044-40-8

[1]Patent:WO2011/150016,2011,A1

[2]Patent:WO2012/71336,2012,A1

[3]Patent:US10213433,2019,B2

Literature fold

Title: Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.

Journal: The New England journal of medicine20180322

Title: Bruton's tyrosine kinase inhibitors: first and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL).

Journal: Expert opinion on investigational drugs20180101

Title: Bcl-2 inhibitors reduce steroid-insensitive airway inflammation.

Journal: The Journal of allergy and clinical immunology20170801

Title: Pharmacokinetics of Venetoclax, a Novel BCL-2 Inhibitor, in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma.

Journal: Journal of clinical pharmacology20170401

Title: Evaluation of Rifampin's Transporter Inhibitory and CYP3A Inductive Effects on the Pharmacokinetics of Venetoclax, a BCL-2 Inhibitor: Results of a Single- and Multiple-Dose Study.

Journal: Journal of clinical pharmacology20161101

Title: Genomics and drug profiling of fatal TCF3-HLF-positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options.

Journal: Nature genetics20150901

Title: ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development.

Journal: Journal of hematology & oncology20150101

Title: ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets.

Journal: Nature medicine20130201

Title: Souers AJ, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013 Feb;19(2):202-8.

Title: Peirs S, et al. ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia. Blood. 2014 Dec 11;124(25):3738-47.

Title: Bi C, et al. Inhibition of 4EBP phosphorylation mediates the cytotoxic effect of mechanistic target of rapamycin kinase inhibitors in aggressive B-cell lymphomas. Haematologica. 2017 Apr;102(4):755-764.